Double Helix Joins McCann Health

LONDON, NEW YORK, PHILADELPHIA and SINGAPORE, June 25, 2012 /PRNewswire/ -- McCann Health, a division of Interpublic Group (NYSE: IPG), announced today the acquisition of Double Helix. Founded in 1995, Double Helix is a leading, global provider of Market Research and Market Access services to the pharmaceutical and medical device industries.  Dr. Wayne Phillips, who founded and runs Double Helix, will continue as CEO of Double Helix, reporting to John Cahill, CEO of McCann Health.

Mr. Cahill said, "For some time, we have been working to elevate all of our offerings by several orders of magnitude. With Double Helix, we now have the basis for the best market research and market access offerings in the business."

Double Helix rounds out McCann Health's impressive suite of services. Its focus on innovation and novel collaborations within its network makes McCann Health the most differentiated and endowed, full-service global healthcare communications company.

Dr. Phillips said, "The arrival of the right partner allows us to leverage our strong reputational position. McCann Health provides us with the resources to create an exciting and fulfilling future through the continued development and further internationalisation of the business."

Double Helix's Market Research division specialises in primary market research for its healthcare clients. The division focuses on the strategic and tactical business needs clients face throughout a product's lifecycle, from pre-clinical to post-launch. The division employs a wide range of qualitative and quantitative techniques to address diverse business objectives, primarily centred on scenario-planning, positioning, communications, market understanding and creative insights.

Double Helix's Market Access Consulting division assists clients to optimise the life cycle position of products in markets. Market Access consulting is the co-ordinated analysis of a number of inter-related activities, including: pricing, reimbursement, health economics and payer decision making-- pre-requisites for the successful launch of a product or therapy and its long-term profit maximisation.

1 2 Next › Last »